Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.66 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28764825 | 0.93 | HDAC1 (0.68) | HPGDHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL10925762 | 0.93 | HDAC1 (0.68) | HPGDHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL13626338 | 0.93 | HDAC1 (0.68) | HPGDHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL11691718 | 0.90 | HDAC2 (0.63) | HPGDHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL2524341 | 0.89 | HPGD (0.68) | HPGDHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL1928392 | 0.86 | LMNA (0.70) | HPGDHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL19020367 | 0.85 | EPHX2 (0.65) | HPGDL3MBTL1 | |
| SCHEMBL3435489 | 0.84 | TRPV1 (0.84) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL13073412 | 0.84 | HDAC3 (0.78) | HPGDHDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL7201053 | 0.84 | L3MBTL1 (0.89) | HPGDHDAC1HDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220655-A1 | METHODS TO OVERCOME DRUG RESISTANCE BY RE-SENSITIZING CANCER CELLS TO TREATMENT WITH A PRIOR THERAPY VIA TREATMENT WITH A T CELL THERAPY | CELGENE CORPORATION (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023209191-A1 | PREP BINDING LIGANDS | UNIVERSITY OF HELSINKI (FI) | 2023-11-02 | — | — | WO | disclosed |
| US-11040951-B2 | Methods and compositions relating to genotoxin colibactin | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| EP-3299463-B1 | ENZYMATIC ENCODING | NUEVOLUTION AS (DK) | 2020-10-21 | — | — | EP | disclosed |
| US-20200055836-A1 | METHODS AND COMPOSITIONS RELATING TO GENOTOXIN COLIBACTIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-02-20 | — | — | US | disclosed |
| EP-3299463-A2 | ENZYMATIC ENCODING | Nuevolution A/S (DK) | 2018-03-28 | — | — | EP | disclosed |
| EP-2348125-B1 | Method for the synthesis of a bifunctional complex | NUEVOLUTION AS (DK) | 2017-06-21 | — | — | EP | disclosed |
| US-8206901-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| US-8206901-B2 | Method for the synthesis of a bifunctional complex | NUEVOLUTION A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2348124-A2 | Synthesis of a bifunctional complex | Nuevolution A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| EP-2348125-A2 | Method for the synthesis of a bifunctional complex | Nuevolution A/S (DK) | 2011-07-27 | — | — | EP | disclosed |
| EP-1558744-B1 | ENZYMATIC ENCODING | NUEVOLUTION AS (DK) | 2011-06-15 | — | — | EP | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | HPGD 1640/4885HDAC1 1968/4885HDAC3 3667/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | HPGD 842/4885HDAC1 2198/4885HDAC3 1900/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | HPGD 1144/4885HDAC1 2631/4885HDAC3 2934/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | HPGD 842/4885HDAC1 2198/4885HDAC3 1900/4885 |
| US-20200055836-A1 | METHODS AND COMPOSITIONS RELATING TO GENOTOXIN COLIBACTIN | CACYBP, MYCBP, CLSPN | HPGD 1849/4885HDAC1 4045/4885HDAC3 3719/4885 |
| US-11040951-B2 | Methods and compositions relating to genotoxin colibactin | CACYBP, MYCBP, CLSPN | HPGD 1849/4885HDAC1 4045/4885HDAC3 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.